✨ Free AI Report
Inhibrx Biosciences, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Inhibrx Biosciences, Inc.
Research Preview

Inhibrx Biosciences, Inc.: Business Overview, Financials & Competitive Analysis

Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing a broad pipeline of novel biologic therapeutic candidates using diverse protein engineering methods. The company's pipeline includes INBRX-1...

Analyst-debate audio for Inhibrx Biosciences, Inc.

AskCyborg analysts argue the bull and bear cases for Inhibrx Biosciences, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Inhibrx Biosciences, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

Clinical-stage biotech with first-to-market potential in orphan oncology indications backed by proprietary protein engineering...

Read the full analyst-debate transcript →
Industry Biopharmaceutical/Oncology Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 15, 2026
AI-Verified Research
30+ Page Report

Get the Latest Inhibrx Biosciences, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Inhibrx Biosciences, Inc. Overview

Pro stress-test →

Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing a broad pipeline of novel biologic therapeutic candidates using diverse protein engineering methods. The company's pipeline includes INBRX-109, a tetravalent therapeutic targeting death-receptor 5 for chondrosarcoma, and INBRX-106, a hexavalent sdAb-based therapeutic targeting OX40 for multiple solid tumor indications.

Strategic Profile

Pro stress-test →

Founded in 2024 and based in La Jolla, California, Inhibrx leverages proprietary modular protein engineering platforms to develop targeted cancer therapeutics. The company's lead candidate ozekibart (INBRX-109) represents potential first-in-class therapy for chondrosarcoma, positioning Inhibrx at the forefront of precision oncology with near-term regulatory catalysts.

Competitive Landscape

Pro stress-test →

Inhibrx competes with biotech firms including Harbour BioMed, NGM Bio, Allakos, and Allogene Therapeutics. The company differentiates through its proprietary protein engineering platform enabling optimized multivalent formats and focus on underdeveloped oncology indications like chondrosarcoma where unmet medical need is substantial.

Industry Context

Inhibrx Biosciences, Inc. operates in Biopharmaceutical/Oncology Therapeutics.

Key facts

Founded: 2024 · Headquarters: La Jolla, US · Employees: 161 · Market cap: $166M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Inhibrx Biosciences, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Inhibrx Biosciences, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Checkpoint Inhibitors & AgonistsPD-1 checkpoint inhibitor being tested in combination with INBRX-106→Early-Stage OncologyCompetitor developing biologic therapeutics→Early-Stage OncologyCompetitor in oncology therapeutics development→

Compare Inhibrx Biosciences, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Inhibrx Biosciences, Inc. operates in Biopharmaceutical/Oncology Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical/Oncology Therapeutics research →
NEW · MCP server

Ask your AI assistant about Inhibrx Biosciences, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Inhibrx Biosciences, Inc. and its top competitor on Cyborg Score”
“What did Inhibrx Biosciences, Inc. do this quarter?”
“Is Inhibrx Biosciences, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Inhibrx Biosciences, Inc. do?+
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing a broad pipeline of novel biologic therapeutic candidates using diverse protein engineering methods. The company's pipeline includes INBRX-1...
What is Inhibrx Biosciences, Inc.'s Cyborg Score?+
Inhibrx Biosciences, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Inhibrx Biosciences, Inc.'s main competitors?+
Named competitors include Checkpoint Inhibitors & Agonists, Early-Stage Oncology, Early-Stage Oncology. The full competitive landscape is in the AskCyborg report.
How can I get the full Inhibrx Biosciences, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Inhibrx Biosciences, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Inhibrx Biosciences, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9National Bank of Pakistan9RENK Group AG9Lumentum Holdings Inc.9First Abu Dhabi Bank9The Travelers Companies, Inc.9BAE Systems plc9Arista Networks9KLA Corporation9Hermès International S.A.8Enerjisa Enerji A.Ş.8Emirates Central Cooling Systems Corporation8WALLIX Group8StealthGas Inc.8SofWave Medical Ltd.8Himalaya Shipping Ltd.8Bannerman Energy Ltd8Sembcorp Salalah Power & Water Company8MilDef Group